Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1977 1
1981 1
1982 1
2005 1
2011 1
2013 1
2014 3
2015 1
2016 2
2017 2
2018 1
2019 3
2020 5
2021 5
2022 6
2023 5
2024 5
2025 7

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

49 results

Results by year

Filters applied: . Clear all
Page 1
Trial of Prasinezumab in Early-Stage Parkinson's Disease.
Pagano G, Taylor KI, Anzures-Cabrera J, Marchesi M, Simuni T, Marek K, Postuma RB, Pavese N, Stocchi F, Azulay JP, Mollenhauer B, López-Manzanares L, Russell DS, Boyd JT, Nicholas AP, Luquin MR, Hauser RA, Gasser T, Poewe W, Ricci B, Boulay A, Vogt A, Boess FG, Dukart J, D'Urso G, Finch R, Zanigni S, Monnet A, Pross N, Hahn A, Svoboda H, Britschgi M, Lipsmeier F, Volkova-Volkmar E, Lindemann M, Dziadek S, Holiga Š, Rukina D, Kustermann T, Kerchner GA, Fontoura P, Umbricht D, Doody R, Nikolcheva T, Bonni A; PASADENA Investigators; Prasinezumab Study Group. Pagano G, et al. N Engl J Med. 2022 Aug 4;387(5):421-432. doi: 10.1056/NEJMoa2202867. N Engl J Med. 2022. PMID: 35921451 Clinical Trial.
Status of Sepsis Care in European Hospitals: Results from an International Cross-Sectional Survey.
Scheer CS, Giamarellos-Bourboulis EJ, Ferrer R, Idelevich EA, Annane D, Artigas A, Aslan AT, Bottari G, Bouma HR, Černý V, Curić Radivojević R, Dakou K, Dewitte K, Elbahnasawy M, Gründling M, Gurjar M, Hästbacka J, Kyprianou M, Laribi S, Lassen A, Lebedinskii K, Máca J, Malbrain MLNG, Monti G, Ostermann M, Osthoff M, Paiva JA, Sabbatucci M, Śmiechowicz J, Ştefan MG, Vollmer M, Vuković N, Zaragkoulias K, Reinhart K, Linder A, Filipescu D; European Sepsis Care Study Group. Scheer CS, et al. Am J Respir Crit Care Med. 2025 Apr;211(4):587-599. doi: 10.1164/rccm.202406-1167OC. Am J Respir Crit Care Med. 2025. PMID: 39787606 Free PMC article.
Air embolism following hysteroscopy.
Luthra N, Namrata, Grewal A. Luthra N, et al. J Anaesthesiol Clin Pharmacol. 2019 Jul-Sep;35(3):416-417. doi: 10.4103/joacp.JOACP_143_18. J Anaesthesiol Clin Pharmacol. 2019. PMID: 31543604 Free PMC article. No abstract available.
Study in Parkinson's disease of exercise phase 3 (SPARX3): study protocol for a randomized controlled trial.
Patterson CG, Joslin E, Gil AB, Spigle W, Nemet T, Chahine L, Christiansen CL, Melanson E, Kohrt WM, Mancini M, Josbeno D, Balfany K, Griffith G, Dunlap MK, Lamotte G, Suttman E, Larson D, Branson C, McKee KE, Goelz L, Poon C, Tilley B, Kang UJ, Tansey MG, Luthra N, Tanner CM, Haus JM, Fantuzzi G, McFarland NR, Gonzalez-Latapi P, Foroud T, Motl R, Schwarzschild MA, Simuni T, Marek K, Naito A, Lungu C, Corcos DM; SPARX3-PSG Investigators. Patterson CG, et al. Among authors: luthra n. Trials. 2022 Oct 6;23(1):855. doi: 10.1186/s13063-022-06703-0. Trials. 2022. PMID: 36203214 Free PMC article.
A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline Data.
Pagano G, Boess FG, Taylor KI, Ricci B, Mollenhauer B, Poewe W, Boulay A, Anzures-Cabrera J, Vogt A, Marchesi M, Post A, Nikolcheva T, Kinney GG, Zago WM, Ness DK, Svoboda H, Britschgi M, Ostrowitzki S, Simuni T, Marek K, Koller M, Sevigny J, Doody R, Fontoura P, Umbricht D, Bonni A; PASADENA Investigators; Prasinezumab Study Group. Pagano G, et al. Front Neurol. 2021 Oct 1;12:705407. doi: 10.3389/fneur.2021.705407. eCollection 2021. Front Neurol. 2021. PMID: 34659081 Free PMC article.
Time-to-event analysis mitigates the impact of symptomatic therapy on therapeutic benefit in Parkinson's disease trials.
Pagano G, Trundell D, Simuni T, Pavese N, Marek K, Postuma RB, Shariati N, Monnet A, Moore E, Davies EW, Svoboda H, Pross N, Bonni A, Nikolcheva T; PASADENA Investigators; Prasinezumab Study Group. Pagano G, et al. NPJ Parkinsons Dis. 2025 Jul 1;11(1):193. doi: 10.1038/s41531-025-01041-9. NPJ Parkinsons Dis. 2025. PMID: 40593721 Free PMC article.
Exploratory digital outcome measures of motor sign progression in Parkinson's disease patients treated with prasinezumab.
Taylor KI, Lipsmeier F, Scelsi MA, Volkova-Volkmar E, Rukina D, Popp W, Lambrecht S, Anzures-Cabrera J, Summers D, Abt M, Monnet A, Kilchenmann T, Schjodt-Eriksen J, Essioux L, Kustermann T, Zago W, Svoboda H, Nikolcheva T, Postuma RB, Pagano G, Lindemann M; PASADENA Investigators; Prasinezumab Study Group. Taylor KI, et al. NPJ Digit Med. 2025 Jun 16;8(1):365. doi: 10.1038/s41746-025-01572-8. NPJ Digit Med. 2025. PMID: 40523921 Free PMC article.
Aerobic exercise-induced changes in fluid biomarkers in Parkinson's disease.
Luthra NS, Mehta N, Munoz MJ, Fantuzzi G, Lamotte G, Haus JM, McFarland NR, Tansey MG, Gonzalez-Latapi P, Caraveo G, Kang UJ, Corcos DM. Luthra NS, et al. NPJ Parkinsons Dis. 2025 Jul 1;11(1):190. doi: 10.1038/s41531-025-01042-8. NPJ Parkinsons Dis. 2025. PMID: 40595707 Free PMC article. Review.
Conformations of proline.
De Tar DF, Luthra NP. De Tar DF, et al. Among authors: luthra np. J Am Chem Soc. 1977 Feb 16;99(4):1232-44. doi: 10.1021/ja00446a040. J Am Chem Soc. 1977. PMID: 833398 No abstract available.
49 results